Lean tissue adjusted peak oxygen consumption in congestive heart failure  by Wensel, Roland & Anker, Stefan D
second revascularization procedure than were those assigned to
CABG. Subsequent major events occuring in such patients would
not be reported. This would bias the mortality and myocardial
infarction rates in favor of PTCR.
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REPLY
We disagree with the comments made by Dr. F. James Brennan
that major events were underreported in our recent Journal article
(1). Although we used a composite end point that included death,
myocardial infarction, cerebrovascular accident and myocardial
revascularization, we also separately reported mortality, myocardial
infarction, repeat revascularization procedures and stroke (1).
For example, as outlined in the Results section, there were
thirteen 30-day deaths in the coronary artery bypass graft (CABG)
group and two deaths in the percutaneous transluminal coronary
revascularization (PTCR) group. After one month, five patients
died in the PTCR group and four in the CABG group. These
deaths are reflected in the Kaplan-Meier survival curves shown in
our Figure 2, demonstrating a better survival in the PTCR group
compared with CABG group (96.9% vs. 92.5%, respectively, p ,
0.017).
We employed the Kaplan-Meier method to estimate length of
survival, freedom from myocardial infarction, freedom from repeat
revascularization procedures and freedom from combined events
for patients treated with CABG and with PTCR (see our Figs.
2–4). Comparison between groups was performed using the
log-rank test. The Kaplan-Meier method is an appropriate means
of estimating survival and other major events in our study. Because
each of the events (mortality, myocardial infarction and repeat
revascularization procedures) was analyzed separately using the
Kaplan-Meier method, there was no under-reporting of major
events. Although a given patient may have experienced a nonfatal
primary end point, he or she was not excluded from the analysis of
the other events. The Kaplan-Meier method allows the estimation
of survival time of each patient who dies and provides exact survival
proportions; this is because it uses exact survival times. The same
principle was applied in the calculation of freedom from myocar-
dial infarction and freedom from repeat revascularization proce-
dures.
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Lean Tissue Adjusted Peak Oxygen
Consumption in Congestive Heart Failure
Osman et al. (1) recently reported data on the prognosis of 225
patients with heart failure. In their analysis they sought to test the
hypothesis that peak oxygen uptake gains prognostic power when
expressed per lean body mass. Taking the present and other
available data (2,3), we entirely agree that this may in fact be
possible. However, we also see a number of problems in the present
article with regard to exercise testing, the patient group itself and
its very low event rate, as well as the statistical analysis. Therefore,
we cannot consider their article to offer proof of its conclusion.
The mean peak oxygen uptake (VO2) of their population of heart
failure patients was 16 ml/kg/min. The mean anaerobic threshold
was 12.7 ml/kg/min, and the peak heart rate was only 126
beats/min. Although mentioned in their Methods section, the
investigators’ data for respiratory exchange ratio at peak exercise, a
marker of metabolic stress, are not given anywhere in their report.
The investigators chose to present event rates based on 14 deaths
and 15 urgent transplants. In other words, the total mortality rate
in this population was about 7% during 19 months of follow-up.
This study group appears on average to have been in mild heart
failure. This low mortality rate is surprising given the mean peak
VO2 of 16 ml/kg/min. Even if urgent transplant is included in the
end point, the 12-month event rate in patients with peak VO2 #14
ml/kg/min is still only about 15%, which seems very low. Using the
same cutoff, Mancini et al. (4) reported a mortality rate of 30% to
53% in 12 months. Taken together, this raises concern about the
validity of their exercise tests, suggesting that an adequate VO2 may
not have been reached.
Whichever way one examines the data, the total event number
of 29 appears too small to perform extensive statistical analyses.
The main statistical analysis in the Osman et al. (1) article is
concerned with comparing peak VO2/weight versus peak VO2/lean
weight as a continuous or dichotomous variable, respectively.
Unfortunately, the receiver-operator curves (ROCs) for the two
continuous variables are not presented, and the arguments are
based on somewhat different chi-square (20.53 vs. 17.17) and p
values (0.0001 vs. 0.0007). No statistical comparison for the two
continuous variables is provided. Also, the comparison of the two
cutoffs appears difficult to interpret.
First, the data in their Table 2 (1) do not specify the follow-up
period to which they relate. Second, calculation of the ROC is
reserved for variables with many different levels. In their Table 2,
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because in each case there is only one cutoff, it is not possible to
calculate an area under the curve (AUC) for ROC as one has only
one data point of corresponding sensitivity and specificity.
Further explanation is necessary. It would be worthwhile to
know how the p values for the differences between the AUCs were
obtained, as the p values seem very small (Table 2) for the
comparison between the two peak VO2 measures.
Additionally, it remains arguable whether the comparison to
Mancini’s cutoff is justified at all, as the cutoff was established in a
much sicker population, whereas the lean cutoff was specifically
designed for this population. Does selection of the optimal peak
VO2/weight cutoff change the predictive power of this variable?
Finally, we cannot consolidate the fact that the confidence interval
for the RR values in their Table 5 (1) encompasses 1.0, yet all p
values are highly significant.
The literature reviewed for the Osman et al. article appears
somewhat incomplete. Using the DEXA-scan, previous studies
have found that absolute peak VO2 (in ml/min) closely relates to
lean tissue mass in patients with congestive heart failure (CHF)
(5,6). That peak VO2/weight underestimates true exercise capacity
in obese patients with CHF (7) and overestimates it in cachectic
patients with CHF (8) has been suggested some years ago.
Finally, the investigators (1) conclude that peak VO2/lean
weight is the cardiopulmonary exercise parameter that provides
“the best risk stratification across the heterogeneous systolic heart
failure cohort.” The presented data do not justify this conclusion.
First, this is due to the above problems, but more importantly this
is because the VE/VCO2-slope (which is automatically provided by
the equipment the authors used) was ignored for all analyses. For
several years now the latter is known to be a strong prognosticator
(9,10) independently of peak VO2. In mild CHF, the VE/VCO2-
slope is even superior to peak VO2 in predicting prognosis (11).
Again, we believe the report by Osman et al. (1) examines an
important subject, and we agree that peak VO2/lean weight is
better than peak VO2/weight, but we also believe this message has
not been proven by these investigators, and that the points we
addressed above could have been beneficially optimized during the
review process.
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REPLY
We appreciate the opportunity to respond to the concerns raised by
Drs. Wensel and Anker, which in our opinion do not affect the
major results and conclusions of our study (1).
Of the 225 patients we studied, 170 (75%) reached anaerobic
threshold (mean VO2 at AT 12.28 6 3.97 ml/kg/min). Addition-
ally, at peak oxygen consumption, the mean respiratory exchange
ratio was 1.09 6 0.14, suggesting an adequate effort for the study
population.
The authors also point out the low mortality rate of our
population, and they compare our major event rate to that of the
smaller and sicker population studied by Mancini et al. (2).
Whereas 46% of our patients were in New York Heart Association
(NYHA) functional class III, 40% in class II and 14% in class I,
70% of the population in Mancini’s study were in NYHA
functional class III, and even 13% in class IV, with only 17% in
class II. In addition, owing to many years separating patient
selection for these two studies, there may be major differences in
overall medical management, including aggressive revasculariza-
tion of patients with ischemic cardiomyopathy, adequate use of
angiotensin-converting enzyme (ACE) inhibition (95% of our
patients) and an evolving mandated use of beta-blockers (31%),
which have likely reduced the morbidity and mortality for our
heart failure patients. However, we believe that our population is
representative of heart failure and cardiac transplant patients
currently presenting to large referral centers in the United States.
In addition, the relatively high percentages of women and, partic-
ularly, obese patients—with both groups having strong trends for
lower major event rates—further contribute to the low overall
event rate noted in our cohort.
The authors refer to several studies that corroborate the evidence
that lean body mass correlates better to peak oxygen consumption.
We regret not having mentioned Dr. Anker’s study using DEXA
scanning, an accurate technique but one that has not gained wide
practical acceptance. In our study we used a simple anthropometric
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